p16 expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4103-4104

  Chung, Christine H ^a   Raben, David ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TIRAPAZAMINE; TRIAZINE DERIVATIVE; TUMOR MARKER; VIRUS DNA;

CANCER RISK; CANCER SURVIVAL; CELL HYPOXIA; EDITORIAL; HUMAN; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WART VIRUS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CHEMISTRY; DISEASE FREE SURVIVAL; GENETICS; MORTALITY; NOTE; OROPHARYNX TUMOR; PAPILLOMA VIRUS; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA, VIRAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; TUMOR MARKERS, BIOLOGICAL;

EID: 77957949655     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.6035     Document Type: Editorial

References (19)

1. D'Souza G, Kreimer AR, Viscidi R, et al: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944-1956, 2007
2. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407-420, 2008 (Pubitemid 351480511)
3. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
4. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008 (Pubitemid 351480538)
5. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al: Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27:1992-1998, 2009
6. INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142-4148, 2010
7. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
8. Shi W, Kato H, Perez-Ordonez B, et al: Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213-6221, 2009
9. Parry D, Bates S, Mann DJ, et al: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503-511, 1995
10. Andl T, Kahn T, Pfuhl A, et al: Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5-13, 1998 (Pubitemid 28027707)
11. Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210-212, 1995
12. Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633, 1996 (Pubitemid 26272001)
13. Grüttgen A, Reichenzeller M, Jünger M, et al: Detailed gene expression analysis but not microsatellite marker analysis of 9p21 reveals differential defects in the INK4a gene locus in the majority of head and neck cancers. J Pathol 194:311-317, 2001 (Pubitemid 32624557)
14. Kong CS, Narasimhan B, Cao H, et al: The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74:553-561, 2009
15. Weinberger PM, Yu Z, Haffty BG, et al: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736-747, 2006 (Pubitemid 46622040)
16. Kumar B, Cordell KG, Lee JS, et al: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008
17. Gillison ML, Zhang Q, Ang K, et al: Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in radiation therapy oncology group (RTOG) protocol 9003. J Clin Oncol 28:423s, 2010 (suppl; abstr 5510)
18. Worden FP, Kumar B, Lee JS, et al: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146, 2008
19. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al: HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94:30-35, 2010